Roger Paredes

26.9k total citations · 1 hit paper
235 papers, 7.7k citations indexed

About

Roger Paredes is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Roger Paredes has authored 235 papers receiving a total of 7.7k indexed citations (citations by other indexed papers that have themselves been cited), including 175 papers in Infectious Diseases, 133 papers in Virology and 48 papers in Epidemiology. Recurrent topics in Roger Paredes's work include HIV Research and Treatment (132 papers), HIV/AIDS drug development and treatment (128 papers) and HIV/AIDS Research and Interventions (94 papers). Roger Paredes is often cited by papers focused on HIV Research and Treatment (132 papers), HIV/AIDS drug development and treatment (128 papers) and HIV/AIDS Research and Interventions (94 papers). Roger Paredes collaborates with scholars based in Spain, United States and United Kingdom. Roger Paredes's co-authors include Bonaventura Clotet, Robert W. Shafer, Vincent Cálvez, Huldrych F. Günthard, Douglas D. Richman, Eugènia Negredo, Marc Noguera-Julián, James D. Lechleiter, Victoria A. Johnson and Deenan Pillay and has published in prestigious journals such as Nature Communications, PLoS ONE and Clinical Infectious Diseases.

In The Last Decade

Roger Paredes

231 papers receiving 7.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

2015 update of the drug resistance mutations in HIV-1

2015 288 citations Vincent Cálvez, Victoria A. Johnson et al. PubMed profile →

Peers

Countries citing papers authored by Roger Paredes

Since Specialization

Citations

This map shows the geographic impact of Roger Paredes's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Roger Paredes with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Roger Paredes more than expected).

Fields of papers citing papers by Roger Paredes

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Roger Paredes. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Roger Paredes. The network helps show where Roger Paredes may publish in the future.

Co-authorship network of co-authors of Roger Paredes

This figure shows the co-authorship network connecting the top 25 collaborators of Roger Paredes. A scholar is included among the top collaborators of Roger Paredes based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Roger Paredes. Roger Paredes is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Doravirine/Islatravir (100/0.75 mg) Once-Daily Compared With Bictegravir/Emtricitabine/Tenofovir Alafenamide as Initial HIV-1 Treatment: 48-Week Results From a Phase 3, Randomized, Controlled, Double-Blind, Noninferiority Trial 2025 ·Clinical Infectious Diseases ·Jürgen K. Rockstroh, Roger Paredes, Pedro Cahn, Jean‐Michel Molina, Simiso Sokhela, Federico Hinestrosa, Sheetal Kassim, Douglas Cunningham, Jade Ghosn, Johannes R. Bogner, Hiroyuki Gatanaga, Ernest Asante‐Appiah, Ying Zhang, (unknown), Stephanie O. Klopfer, Karen Eves, Kathleen Squires, (unknown), Michelle C. Fox, (unknown)	0
2	Predictors of virological outcomes after analytical interruption of antiretroviral therapy and HTI vaccination in early treated people with HIV-1._ 2025 ·Communications Medicine ·Lucía Bailón, (unknown), José Ramón Arribas, Adrián Curran, Anuska Llano, Samandhy Cedeño, Roger Paredes, Elena Vendrame, Devi SenGupta, Jeffrey J. Wallin, Romas Geleziunas, (unknown), Ian McGowan, Christian Brander, José Moltó, Beatriz Mothe	0
3	Precision biotic as an effective replacement of hydrolyzed yeast and butyrate in antibiotic free diets of broiler chickens raised under field conditions 2024 ·Poultry Science ·Cristiano Bortoluzzi, Mahdi Ghanbari, (unknown), (unknown), Roger Paredes, (unknown), (unknown)	1
4	Modifiable lifestyle factors and the risk of post-COVID-19 multisystem sequelae, hospitalization, and death 2024 ·Nature Communications ·Yunhe Wang, Binbin Su, (unknown), Nicola L. Barclay, Yaohua Tian, Chunxiao Li, Nicholas J. Wareham, Roger Paredes, Junqing Xie, Daniel Prieto‐Alhambra	11
5	Deep-amplicon sequencing of the complete beta-tubulin gene in Trichuris trichiura before and after albendazole treatment 2024 ·International Journal for Parasitology Drugs and Drug Resistance ·Javier Gandasegui, (unknown), (unknown), (unknown), (unknown), Anélsio Cossa, (unknown), Charfudin Sacoor, Eric A. T. Brienen, Francesc Català‐Moll, (unknown), María Martínez Valladares, Roger Paredes, José Muñóz, Stephen R. Doyle	1
6	Cardiometabolic health in people with HIV: expert consensus review 2024 ·Journal of Antimicrobial Chemotherapy ·Rachel L. Batterham, Roger Bedimo, Ricardo Sobhie Diaz, Giovanni Guaraldi, Janet Lo, Estebán Martínez, Grace A. McComsey, Ana Milinkovic, (unknown), Sebastian Noé, Donal O’Shea, Roger Paredes, Jonathan Schapiro, Mark Sulkowski, François Venter, Laura Waters, (unknown), Benjamin Young	7
7	Grover-QAOA for 3-SAT: quadratic speedup, fair-sampling, and parameter clustering 2024 ·Quantum Science and Technology ·(unknown), Roger Paredes, Bhuvanesh Sundar, (unknown), Anastasios Kyrillidis, Leonardo Dueñas‐Osorio, Guido Pagano, Kaden R. A. Hazzard	5
8	Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19 2023 ·The Lancet Infectious Diseases ·Robert Gottlieb, Roger Paredes	0
9	The burden of post-acute COVID-19 symptoms in a multinational network cohort analysis 2023 ·Nature Communications ·Kristin Kostka, Elena Roel, Nhung TH Trinh, (unknown), Antonella Delmestri, Lourdes Mateu, Roger Paredes, Talita Duarte‐Salles, Daniel Prieto‐Alhambra, Martí Català, Annika M. Jödicke	9
10	Integrase resistance emergence with dolutegravir/lamivudine with prior HIV-1 suppression 2022 ·Journal of Antimicrobial Chemotherapy ·Boris Revollo, Laura Viñuela, Lorena de la Mora, Féderico García, Marc Noguera-Julián, Mariona Parera, Roger Paredes, Josep M. Llibre	12
11	Effectiveness of integrase strand transfer inhibitor-based regimens in HIV-infected treatment-naive individuals: results from a European multi-cohort study 2021 ·Journal of Antimicrobial Chemotherapy ·Barbara Rossetti, Massimiliano Fabbiani, Domenico Di Carlo, Francesca Incardona, Ana Abecasis, Perpétua Gómes, Anna María Geretti, Carole Seguin‐Devaux, Féderico García, Rolf Kaiser, Sara Modica, (unknown), Anders Sönnerborg, Maurizio Zazzi, (unknown), Bobkova Mr, Roger Paredes, Murat Sayan, Anne–Mieke Vandamme	6
12	Gut microbiome comparability of fresh-frozen versus stabilized-frozen samples from hospitalized patients using 16S rRNA gene and shotgun metagenomic sequencing 2019 ·Scientific Reports ·(unknown), Mette Jørgensen, Marc Noguera-Julián, Gedske Daugaard, Daniel D. Murray, Marie Helleberg, Roger Paredes, Jens Lundgren, Henrik Sengeløv, Cameron Ross MacPherson	22
13	Balances: a New Perspective for Microbiome Analysis 2018 ·mSystems ·Javier Rivera, Juan José Egozcue, Vera Pawlowsky‐Glahn, Roger Paredes, Marc Noguera-Julián, M. Luz Calle	194
14	Mechanisms of Abrupt Loss of Virus Control in a Cohort of Previous HIV Controllers 2018 ·Journal of Virology ·Míriam Rosás-Umbert, Anuska Llano, Rocío Bellido, Àlex Olvera, Marta Ruiz‐Riol, Muntsa Rocafort, Marco A. Fernández, Patricia Cobarsí, Manel Crespo, Lucy Dorrell, Jorge del Romero, José Alcamı́, Roger Paredes, Christian Brander, Beatriz Mothe	30
15	Richer gut microbiota with distinct metabolic profile in HIV infected Elite Controllers 2017 ·Scientific Reports ·Jan Vesterbacka, Javier Sandoval, Kajsa Noyan, Mariona Parera, Ujjwal Neogi, M. Luz Calle, Roger Paredes, Anders Sönnerborg, Marc Noguera-Julián, Piotr Nowak	68
16	Oral microbiome in HIV-associated periodontitis 2017 ·Medicine ·Marc Noguera-Julián, Yolanda Guillén, (unknown), David Reznik, (unknown), Sandeep J. Joseph, Javier Rivera, Sunil Kannanganat, Rama Rao Amara, Minh Ly Nguyen, Simon Mutembo, Roger Paredes, Timothy D. Read, Vincent C. Marconi	41
17	2015 Update of the Drug Resistance Mutations in HIV-1. 2016 ·PubMed ·Annemarie M. J. Wensing, Vincent Cálvez, Huldrych F. Günthard, Victoria A. Johnson, Roger Paredes, Deenan Pillay, Robert W. Shafer, Douglas D. Richman	56
18	European recommendations for the clinical use of HIV drug resistance testing: 2011 update. 2011 ·PubMed ·Anne–Mieke Vandamme, Ricardo Camacho, Francesca Ceccherini‐Silberstein, Andrea De Luca, Lucia Palmisano, Dimitrios Paraskevis, Roger Paredes, Mario Poljak, Jean‐Claude Schmit, Vincent Soriano, Hauke Walter, Anders Sönnerborg	104
19	Calcineurin Interacts with PERK and Dephosphorylates Calnexin to Relieve ER Stress in Mammals and Frogs 2010 ·PLoS ONE ·(unknown), Roger Paredes, Deborah Holstein, Nadezhda N. Zheleznova, Patricia Camacho, James D. Lechleiter	78
20	Epidemiological Data of Different Human Papillomavirus Genotypes in Cervical Specimens of HIV-1-Infected Women Without History of Cervical Pathology 2009 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Sebastián Videla, Laila Darwich, M. Paz Cañadas, Roger Paredes, Antoni Tarrats, Eva Castellà, Mariona Llatjós, Margarita Bofill, Bonaventura Clotet, Guillem Sirera	21

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact